CommercialCoverageHigh impact
Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy 6.01.12
Excellus BlueCross BlueShield·Oncology, Neurosurgery, Radiology +1 more·Radiation Treatment
Effective date
Nov 16, 2025
We identified it
Jun 20, 2026
Summary
Excellus BlueCross BlueShield updated their policy for Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT), establishing detailed coverage criteria for brain tumors, metastases, and various cancer types including specific patient performance status requirements and lesion count/size limitations. The policy includes expanded coverage for oligometastatic disease treatment with strict qualifying criteria.
Action Required
By November 16, 2025: Review all pending and future SRS/SBRT authorizations to ensure they meet the new detailed criteria including ECOG performance status documentation, lesion count and size measurements, and specific cancer staging requirements. Update prior authorization workflows to verify all qualifying conditions are met before treatment approval. Train staff on the new oligometastatic disease criteria and documentation requirements.